KALA BIO, Inc.
KALA
Last
$0.30
Day
+1.1%
1y
-99.6%
5y
-100.0%
52w
-99.7%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1838d
EMA 21
0.46
EMA 50
0.83
EMA 200
36.94
20d high
-51.5%
5y high
-100.0%
5y range
0th
Positions held
Your positionsKALA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$0.41
Stop
$0.20
Stop distance
33.3%
Target vs last
+36.8%
Fundamentals
| Market cap | $5.74M | Enterprise value | -$1.49M | Trailing P/E | — | Forward P/E | -0.04 |
| PEG | — | Price / book | 0.63 | Beta | -2.41 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -3.5% | ROA | -65.4% | Debt / equity | — |
| Current ratio | 6.88 | Free cash flow | -$18.42M | Analyst recommendation | none | Mean target | — |
| 52w high | $95.50 | 52w low | $0.29 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$1.6M | -$1.6M | $0.7M | -$7.6M | -$11.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.7M | -$1.8M | -$10.2M | -$10.2M | -$10.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $3.9M | — |
| Op margin | — | — | — | -2090.3% | — |
| Net income | -$27.0M | -$38.5M | -$42.2M | -$44.8M | — |
| Gross margin | — | — | — | 34.2% | — |
| Gross profit | — | — | $0.0M | $1.3M | $7.1M |
| Operating income | -$39.0M | -$34.2M | -$34.3M | -$81.4M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-17 · KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
2026-09-03 · Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests
2026-09-01 · Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
2026-08-19 · KALA BIO: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patternsKALA · daily-50.5% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin